Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL7336953

NN=Cc1ccc2cc(C#CCNC(=O)c3cccc(N)c3)ccc2c1.O=C(O)C(F)(F)F

nearest known ligand 0.36

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KAT6A Q92794 1/20 0.36
GRM5 P41594 1/20 0.35
ACACB O00763 2/20 0.35
PTGS1 P23219 2/20 0.34
EPHX2 P34913 4/20 0.34
ALOX5 P09917 3/20 0.34
KDM4E B2RXH2 2/20 0.33
ALDH1A1 P00352 1/20 0.33
SOST Q9BQB4 1/20 0.32
FFAR1 O14842 1/20 0.32
PIN1 Q13526 1/20 0.32
MAPT P10636 2/20 0.32
POLB P06746 1/20 0.32
F10 P00742 1/20 0.32
HTT P42858 1/20 0.32
MCHR1 Q99705 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL7334272 0.90 SOST (0.38) ACACBEPHX2KDM4EALDH1A1SOST
Trifluoroacetic Acid SCHEMBL7334287 0.90 SOST (0.38) ACACBEPHX2KDM4EALDH1A1SOST
Trifluoroacetic Acid SCHEMBL7336945 0.83 ASIC3 (0.46) F10
SCHEMBL7337900 0.77 PLAU (0.45) KAT6AGRM5KDM4EALDH1A1MCHR1
Trifluoroacetic Acid SCHEMBL7334279 0.72 ASIC3 (0.46) KDM4ESOSTMAPTF10
Trifluoroacetic Acid SCHEMBL7338135 0.70 PTGS1 (0.48) PTGS1POLB
Trifluoroacetic Acid SCHEMBL7338119 0.70 PTGS1 (0.48) PTGS1POLB
Trifluoroacetic Acid SCHEMBL7344358 0.69 MEN1 (0.50) POLBHTT
Trifluoroacetic Acid SCHEMBL7344371 0.69 MEN1 (0.50) POLBHTT
Trifluoroacetic Acid SCHEMBL7344126 0.68 PLAU (0.58)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 US disclosed
US-6284796-B1 NAPHTHAMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-09-04 US disclosed
US-6258822-B1 ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-07-10 US disclosed
EP-1000018-A2 UROKINASE INHIBITORS Abbott Laboratories (US) 2000-05-17 EP disclosed
WO-1999005096-A2 UROKINASE INHIBITORS ABBOTT LABORATORIES (US) 1999-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010049374-A1 Urokinase inhibitors SERPINE1, PLAU, SERPINB1 KAT6A 3693/4885GRM5 4207/4885ACACB 2018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.